344 related articles for article (PubMed ID: 25314935)
21. Fluorescent sensors of protein kinases: from basics to biomedical applications.
Nhu Ngoc Van T; Morris MC
Prog Mol Biol Transl Sci; 2013; 113():217-74. PubMed ID: 23244792
[TBL] [Abstract][Full Text] [Related]
22. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
Wesierska-Gadek J; Krystof V
Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
[TBL] [Abstract][Full Text] [Related]
23. Novel arylazopyrazole inhibitors of cyclin-dependent kinases.
Jorda R; Schütznerová E; Cankař P; Brychtová V; Navrátilová J; Kryštof V
Bioorg Med Chem; 2015 May; 23(9):1975-81. PubMed ID: 25835357
[TBL] [Abstract][Full Text] [Related]
24. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
25. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
Law ME; Corsino PE; Narayan S; Law BK
Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
31. High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.
Heeres JT; Hergenrother PJ
Chem Soc Rev; 2011 Aug; 40(8):4398-410. PubMed ID: 21140010
[TBL] [Abstract][Full Text] [Related]
32. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
33. Whether to target single or multiple CDKs for therapy? That is the question.
Węsierska-Gądek J; Maurer M; Zulehner N; Komina O
J Cell Physiol; 2011 Feb; 226(2):341-9. PubMed ID: 20836132
[TBL] [Abstract][Full Text] [Related]
34. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
Malínková V; Vylíčil J; Kryštof V
Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
[TBL] [Abstract][Full Text] [Related]
36. Fluorescent Peptide Biosensors for Probing CDK Kinase Activity in Cell Extracts.
Pellerano M; Morris MC
Methods Mol Biol; 2021; 2329():39-50. PubMed ID: 34085214
[TBL] [Abstract][Full Text] [Related]
37. Regulation of cyclin-dependent kinase 4 during adipogenesis involves switching of cyclin D subunits and concurrent binding of p18INK4c and p27Kip1.
Phelps DE; Xiong Y
Cell Growth Differ; 1998 Aug; 9(8):595-610. PubMed ID: 9716177
[TBL] [Abstract][Full Text] [Related]
38. Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action.
Łukasik P; Baranowska-Bosiacka I; Kulczycka K; Gutowska I
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802080
[TBL] [Abstract][Full Text] [Related]
39. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
Abate AA; Pentimalli F; Esposito L; Giordano A
Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging.
Torres-Guzmán R; Chu S; Velasco JA; Lallena MJ
J Biomol Screen; 2013 Jun; 18(5):556-66. PubMed ID: 23307837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]